DBV Technologies SA
(NASDAQ : DBVT)

( )
DBVT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 4.03%69.701.0%$1071.78m
BIIBBiogen, Inc. 0.02%336.711.5%$665.47m
AMGNAmgen, Inc. 0.29%222.791.3%$550.81m
ILMNIllumina, Inc. -1.50%295.943.5%$414.21m
VRTXVertex Pharmaceuticals, Inc. 0.49%246.291.9%$346.37m
REGNRegeneron Pharmaceuticals, Inc. 1.01%403.152.6%$345.56m
ALXNAlexion Pharmaceuticals, Inc. 0.59%103.142.0%$220.13m
AAgilent Technologies, Inc. 0.85%85.061.6%$165.05m
EXASEXACT Sciences Corp. -2.59%99.9824.0%$144.57m
INCYIncyte Corp. -2.27%80.892.5%$113.92m
SGENSeattle Genetics, Inc. -1.12%117.006.1%$113.16m
BMRNBioMarin Pharmaceutical, Inc. 6.13%95.164.3%$102.95m
MRNAModerna, Inc. -1.67%18.230.0%$98.70m
XLRNAcceleron Pharma, Inc. -0.36%94.516.1%$91.83m
ALNYAlnylam Pharmaceuticals, Inc. -1.57%131.038.7%$91.49m

Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.